Status:
UNKNOWN
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Lead Sponsor:
Samsung Medical Center
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent radiotherapy for inoper...
Eligibility Criteria
Inclusion
- Histologically confirmed squamous esophageal cancer
- The clinical stage T2-3N0M0 or T1-3N1-3M0
- Inoperable case: it refers to medically inoperable status and/or patient's refusal to surgery and/or cervical location and/or locoregionally recurrent tumor after primary surgery
- ECOG PS of 0 to 1
Exclusion
- clinical T4 disease (for example, invasion to aorta, vertebral body, or trachea/bronchus) or distant metastasis (M1)
- previously received radiotherapy for esophageal cancer
Key Trial Info
Start Date :
December 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03377400
Start Date
December 14 2017
End Date
December 30 2021
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, MA, South Korea, 06351